20 January 2025, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has achieved remarkable milestones in medical education over the past seven years since its opening in 2018. From offering pioneering residency and fellowship programs that empower medical trainees to hosting globally recognized conferences, Sidra Medicine has transformed Qatar’s healthcare landscape and positioned itself as a reputable institution for medical expertise.

Prof. Ibrahim Janahi, Acting Chief Medical Officer and Chair of Medical Education at Sidra Medicine said: “When Sidra Medicine’s Medical Education pillar was established, our mission was to be ranked among the top academic medical centers in the world. I am pleased to see how far we have come on this journey and the big strides we have taken to develop the next generation of healthcare and research professionals. Our world-class events have positioned Qatar as a premier hub in the region for advancing medicine and research, attracting experts and delegates from around the world. As a proud Qatari institution, we are dedicated to empowering local and regional talent while maintaining a global outlook.”

The Medical Education Department at Sidra Medicine vision is to set the highest standards of medical education and continuous professional development opportunities for healthcare professionals and offer medical trainees an exceptional educational experience to create safe and competent future doctors specialized in children’s and women’s health.

“Each year Sidra Medicine offers thousands of education sessions with well over 10,000 credit hours. Our wide variety of offerings include workshops, medical simulations, seminars, symposia, grand rounds, conferences, journal clubs, and blended online learning modules. By transferring knowledge and advancing healthcare education, we are not only shaping the future of medicine but also fulfilling our mission to serve the unique needs of the Arab population,” continued Prof. Janahi.

Sidra Medicine supports medical students’ clerkships and placements in pediatric and women’s healthcare, serving as a specialist teaching hospital for students from Weill Cornell Medicine-Qatar and Qatar University Medical College as well as research students from Hamad Bin Khalifa University. Since 2018, over 1,000 medical students completed their clerkship programs at Sidra Medicine, additionally, over 400 residents and fellows have graduated from Sidra Medicine’s pediatric residency and fellowship programs, which are accredited by the Accreditation Council for Graduate Medical Education – International (ACGMEI).

The hospital’s medical education achievements also include institutional accreditation from the Royal College of Physicians and Surgeons of Canada, enabling it to accredit residency training programs across multiple specialties. These efforts have elevated Sidra Medicine’s standing as a premier academic and healthcare institution. Its impact is further evidenced by its partnerships with leading institutions such as the Children’s Hospital of Philadelphia.

Sidra Medicine also offers innovative programs like the Introduction to Genomics (InGen) workshops, which in 2024 provided over 400 high school students with hands-on research experience.

Sidra Medicine has established itself as a hub for international medical and research conferences and workshops, bringing globally renowned events to Qatar. In the past ten years, Sidra Medicine has hosted many events and conferences that have collectively drawn over 20,000 healthcare professionals and researchers. Notably, these gatherings have welcomed over 1,000 international participants from more than 23 countries, highlighting Sidra Medicine’s role in fostering global collaboration and knowledge exchange

All its conferences and workshops offer Continuous Medical Education (CME) and Continuing Professional Development (CPD) points which are accredited by the Department of Healthcare Professionals.

In 2024, Sidra Medicine hosted the 31^st Annual Scientific Meeting of the Middle East Fertility Society (MEFS), the largest organization in the region dedicated to advancing fertility care. In 2019, it proudly hosted the 6^th World Congress of the World Federation of Associations of Pediatric Surgeons (WOFAPS), attracting over 800 surgeons from more than 80 countries. This landmark event, held for the first time in the Middle East, underscored Qatar’s emergence as a premier destination for advancing pediatric surgical care.

Its annual conferences, such as the Precision Medicine and the Future of Genomics Summit (PMFG) and the Pediatric Neuroscience Conference (PNC) have become signature events, attracting participants from across the Middle East and beyond.

Sidra Medicine’s upcoming Gulf Pediatric Critical Care Conference (GPCCC) from 23 to 26 January is a testament to its ongoing dedication to providing access to cutting-edge education and medical education, as it is the first of its kind to be held in the Gulf Cooperation Council (GCC) region. Online slots are still available. Register virtually here.

For additional information about Medical Education at Sidra Medicine, please visit: https://www.sidra.org/education/medical-education

22 December 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has signed a contractual agreement with MSH International,a global leader in medical insurance services.

The new partnership will broaden Sidra Medicine’s reach, allowing the hospital to provide quality healthcare services to a wider range of patients and families, while ensuring affordability and accessibility.

The agreement marks a significant milestone for Sidra Medicine, as it integrates MSH International into its network of insurance providers. The collaboration will facilitate direct billing for patients covered under MSH International plans, streamlining access to Sidra Medicine’s world-class women’s and pediatric services.

Dr. Iyabo Tinubu-Karch, Chief Executive Officer at Sidra Medicine, said: “Our partnership with MSH International highlights our commitment to making healthcare more accessible and seamless for our patients. Collaborating with a globally trusted insurance provider network ensures that patients can prioritize their health, supported through a system designed to streamline access to care. At Sidra Medicine, patient well-being remains at the heart of every connection we build and every partnership we develop.”

A reputable insurance provider with over 10,000 corporate clients and a strong presence in the GCC region, MSH International is recognized for its comprehensive medical insurance offerings.

Mr. Laurent Bonhote, CEO of MSH MENA, stated: “This collaboration with Sidra Medicine represents a significant milestone in our mission to deliver world-class healthcare solutions to our clients across the region. Partnering with one of Qatar’s premier healthcare institutions further solidifies our dedication to enhancing accessibility, driving innovation, and placing patient-centered care at the forefront. Together, we are committed to ensuring patients and families benefit from exceptional services in a streamlined and supportive environment.”

15 December 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has become the first hospital in the region to successfully perform a high-risk cesarean section (C-section) in its state-of-the-art angiography suite. The procedure, a collaboration between the hospital’s Interventional Radiology (IR) and Obstetrics teams, marks a significant advancement in maternal care for high-risk pregnancies.

The angiography suite – a highly specialized operating room equipped with advanced imaging technology – provides the ideal environment for procedures requiring precise image guidance. For patients at high risk of bleeding during delivery, performing the C-section in this setting allows for immediate access to critical interventions like endovascular embolization.

Prof. Johnny Awwad, Chair of Women’s Services at Sidra Medicine, said: “Traditionally, IR teams have provided backup support for high-risk deliveries performed in the obstetrics operating rooms (OR). However, patient transfer times from the obstetrics OR to the IR suite are lengthy, especially when patients are unstable and we have to factor several safety protocols. This multidisciplinary collaboration between obstetrics and IR, is what makes a difference in successfully managing high-risk pregnancies. It truly sets our hospital apart in terms of offering women in Qatar, access to the most innovative therapies, expert teams and transformative care.”

Performing C-sections for high-risk patients directly in the angiography suite, can significantly reduce transfer times from the obstetrics waiting room to the IR from approximately 60 minutes to zero. This approach will allow for faster intervention if bleeding occurs.

Dr. Walid Mubarak, Interventional Radiology Attending Physician and Clinical Lead at Sidra Medicine, said: “For women at high risk of postpartum hemorrhage, this technique can be lifesaving. The angiography suite allows us to instantly access cutting-edge technology and perform minimally invasive procedures. We can quickly navigate the patient’s blood vessels with tiny catheters and precisely deliver embolic agents to stop bleeding. This minimizes blood loss and significantly improves the chances of a healthy outcome for both mother and baby.”

Sidra Medicine’s pioneering approach to addressing postpartum hemorrhage (PPH) offers a critical solution for one of the leading causes of maternal mortality worldwide. Affecting approximately 1-10 percent1 of deliveries, PPH is responsible for about 27 percent of maternal deaths globally. Sidra Medicine’s innovative use of an angiography suite for high-risk deliveries sets a new benchmark for maternal care.

Dr. Ashley Robinson,  Vice Chair of Radiology at Sidra Medicine, said: “This achievement demonstrates the power of integrated care, which is central to Sidra Medicine’s approach. In addition to IR and Obstetrics, we have adult anesthesia and dedicated neonatal intensive care specialists present, ensuring seamless, coordinated care for both mother and baby, all within the angiography suite. This innovative approach enhances safety and care for women undergoing high-risk deliveries.”

Patients at Sidra Medicine who are considered at risk for bleeding during delivery are encouraged to discuss this approach with their obstetrician to determine if it is the right option for them. Contact us at 4003 3333 to learn more about our maternity services.  

4 December 2024, Doha, Qatar –  A groundbreaking study by Sidra Medicine, a member of Qatar Foundation, has been published in ‘Genetics in Medicine’, an official journal of the American College of Medical Genetics and Genomics.  Titled “Mapping the Genetic Landscape of Treatable Inherited Metabolic Disorders in a large Middle Eastern Biobank”, the study was also the recipient of the journal’s Editor’s Choice Award.

Done in collaboration with the Qatar Precision Health Institute (QPHI) and led by Dr. Khalid Fakhro, Chief Research Officer and first authored by Dr. Geethanjali Devadoss Gandhi, Senior Postdoctoral Fellow at Sidra Medicine, the study analyzed the genome sequencing data of more than 14,000 participants from QPHI, focusing on 125 genes associated with 115 treatable IMDs. 

Inherited Metabolic Disorders (IMDs) are a group of rare conditions caused by enzyme deficiencies with a genetic basis that disrupt the body’s metabolism. Although each IMD is rare, their collective incidence is considerable, commonly estimated at 1 in 2,500 to 5,000 live births.

Prof. Khalid Fakhro said: “Our study fills a critical gap by focusing on the Qatari population, which has been underrepresented in previous genomic datasets. By analyzing the QPHI data, we identified 69 types of treatable IMDs within the Qatari population. Understanding the true prevalence of such metabolic disorders through genetic carrier and newborn screenings, particularly in countries with higher consanguinity rates, can offer us a detailed methodology for future investigations in population biobanks.”

The Sidra Medicine led study revealed a significant carrier frequency1 and disease burden2 for 46 treatable IMDs within the Qatari population. The results showed that approximately 1 in 13 unrelated individuals (eight percent) were carriers of at least one of these IMDs, with thirty-one participants (0.2 percent) carrying more than one disease-causing variant.

It also highlighted a concerning trend with inherited disorders like phenylketonuria (PKU)/ hyperphenylalaninemia and homocystinuria, which exhibited high carrier frequencies (1 in 68 and 1 in 85, respectively) within the Qatari population. The estimated disease burden in the population stands at 1 in 5,038 for PKU/hyperphenylalaninemia and 1 in 6,315 for homocystinuria.

Dr. Geethanjali Devadoss Gandhi said: “Our findings were particularly significant considering that data on PKU/hyperphenylalaninemia prevalence among Qataris is currently unavailable. It underscores the immediate need for further comprehensive research on treatable inherited metabolic disorders. We are hopeful that such research will also lay the ground for new treatment options to address previously unrecognized health concerns within the Qatari population.”

Dr. Ammira Al-Shabeeb Akil, Principal investigator and the lead of Genetics and Metabolic Clinical research program added: “Our study emphasizes the importance of extensive population

screenings across the MENA region. This will pave the way for precision medicine therapies tailored to specific populations.  To that end, we believe that our joint Newborn Genome Screening Research Program in collaboration with Hamad Medical Corporation, will help with the early diagnosis of genetic conditions in babies in the general population in Qatar.”

The Sidra Medicine treatable IMD study was also awarded first place for ‘abstract presentation’ at the MENA Congress for Rare Diseases 2024 in Abu Dhabi, highlighting its far-reaching impact on other Arab populations. ​

4 December 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, concluded the second day of its Precision Medicine and the Future of Genomics (PMFG 2024) Summit today.

PMFG 2024 continued to deliver impactful discussions, uniting global experts to explore groundbreaking ideas in precision medicine and genomics. The summit featured dynamic sessions and a high-profile panel addressing the opportunities and challenges of building a robust biomedical innovation economy in Qatar.

A highlight of Day two, was the panel powered by Doha Debates, which explored the theme “Shaping the Future: Exploring the Boundaries of Human Advancement.” Moderated by Al Jazeera’s Dareen Abu Ghaida, the discussion tackled the ethical and philosophical implications of advancing genomics and biotechnology. 

Panelists included Jamie Metzl (Entrepreneur and Sci-Fi Novelist), Dr. Sarah Chan (The University of Edinburgh, UK), and Dr. Arash Rafii (Weill Cornell Medical-Qatar).

Dr. Sarah Chan, Center for Biomedicine, Self and Society, Usher Institute, The University of Edinburgh, UK, said: “Genomic medicine offers unparalleled opportunities to revolutionize healthcare, but achieving genomic justice requires addressing inequalities embedded in our systems. By better understanding genome and its benefits for the long run, we can move toward personalized treatments tailored to individual needs, no matter how unique. This transformative shift must be supported by a fairer, more innovative approach to developing cures for the genomic era, ensuring that the benefits of these advancements are accessible to all.”

The second panel session chaired by Dr. Iyabo Tinubu-Karch, CEO of Sidra Medicine, which convened thought leaders from academia, healthcare, and policymaking, focused on positioning Qatar as a global biomedical hub.

Panelists included Dr. Francis Yeoh (National University of Singapore), Dr. Mohamed Adel Ghanem (Qatar Investment Authority), Dr. Slim Slama (World Innovation Summit for Health), Dr. Gordan Sanghera (Oxford Nanopore Technologies), and Dr. Peter Owotoki (Vitafluence.AI).

Dr. Francis Yeoh, Professorial Fellow and Chairman, Innovation & Entrepreneurship – National University of Singapore and Advisor to the Qatar Research, Development and Innovation Council, said: “To build a successful biomedical ecosystem, there are six key components: strong government policies supporting innovation and business, access to cutting-edge healthcare markets, a growing pool of skilled talent, available funding through venture capital and government grants, robust support services like legal aid, startups, and accelerators, and a culture that embraces innovation. Qatar has all of these essential elements in place – positioning it to become a leading biomedical hub.”

Dr. Mohamed Adel Ghanem, Head of Healthcare at Qatar Investment Authority, said: “This event highlights Qatar’s progress and its ambition to lead in biomedical innovation. With advanced facilities like those at Sidra Medicine and access to comprehensive patient datasets, Qatar is well positioned to attract global partners and accelerate impactful solutions. Focusing on local health needs and creating a supportive regulatory environment gives the country a competitive edge to address global healthcare challenges.”

Dr. Slim Slama, CEO at the World Innovation Summit for Health, said: “Qatar is a small yet remarkably agile nation with a clear vision for public health, technology, and investment. In a short time, it has made significant contributions to global health dialogue and innovation. It’s essential to ensure these discussions are inclusive and address the unique needs of regions like ours, where challenges range from infectious diseases to chronic conditions.”

The final day of PMFG 2024 (Thursday 5 December) promises sessions on custom-made therapies, innovative clinical trials, and dialogue in gene therapy. Keynote speakers include Dr. Hakon Hakonarson (Children’s Hospital of Philadelphia), Dr. Chantal Mathieu (European Association for the Study of Diabetes), and Dr. James Wilson (Gemma Biotherapeutics), who will explore actionable insights in genomics and rare disease treatments.  

PMFG 2024 is held under the patronage of the Human Genome Organization (HUGO) and the Global Alliance for Genomics and Health, with Qatar Precision Health Institute as a strategic partner, the Children’s Hospital of Philadelphia as a knowledge partner, Qatar National Bank as the Official Diamond Patronage and Sponsor, and Msheireb Museums as a community partner.

For the complete agenda and session details, visit: https://www.sidra.org/events/research/pmfg/2024/program/. ​

3 December 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, today celebrated a decade of innovation in genomic medicine with the opening of its 10th annual Precision Medicine and the Future of Genomics (PMFG 2024) Summit at QNCC.

Day 1 of PMFG 2024, being held in Doha from December 3-5, welcomed 1,100 attendees, featured over 50 distinguished speakers and showcased over 42 booths from sponsors and partners, who gathered to explore the latest advancements in personalized healthcare, genomic research, and the ethical considerations surrounding this rapidly evolving field.

Ms. Khadija Benganna from Al Jazeera Arabic was the Master of Ceremonies who opened the event with stories of hope featuring patient narratives.

PMFG 2024 Chairs, Dr. Ammira Al-Shabeeb Akil and Prof. Khalid Fakhro said: “PMFG serves as a vital platform for collaboration in precision health, bringing together the brightest minds to drive innovation and progress. Let’s all work towards hope for future generations by building partnerships and pushing the boundaries of personalized healthcare.”

Sessions on Day 1 of PMFG 2024 focused on advancements in genomic newborn screening, rare disease diagnosis, and population genomic cohorts. Discussions explored the ethical, legal, and social implications of integrating genomic data into healthcare, strategies for early detection and personalized treatment, and the role of international collaborations in shaping global genomic research.

Dr. Iyabo Tinubu-Karch, Chief Executive Officer of Sidra Medicine delivered her welcoming remarks at the opening ceremony of the PMFG 2024 Summit. Speaking about the significance of the event, she stated: “I am proud of the progress we have achieved and of how PMFG has evolved into a platform where the brightest talent and minds come together annually. Our shared insights into the latest research and best practices have a profound impact on patient populations globally, especially in the areas of genetic and rare diseases. “

Dr. Robert Green, Director of the Genomes2People Research Program at Harvard Medical School, delivered a compelling keynote address titled ‘The Path to Lifelong Genomic Medicine’: “Since the days of the Human Genome Project, people have envisioned a future where medicine transitions from reactive to proactive, and even to preventive. We are entering a new era, with large-scale studies launching globally to generate evidence on how genomics can be used in screening. The next frontier is not just newborn sequencing, but lifelong genomics-informed healthcare that is accessible to all.”

In her opening remarks, Dr. Akil emphasized PMFG’s key goals, stating: “Our mission is to promote innovation in precision medicine, driving breakthroughs in genomics to enhance personalized healthcare and improve patient outcomes. This summit also serves as a platform for empowering knowledge sharing, where insights on cutting-edge research, clinical applications, and emerging technologies in genomics can be exchanged to shape the future of healthcare.”

Dr. Chantal Mathieu, President of the European Association for the Study of Diabetes (EASD), took part in the opening panel of the PMFG 2024 Summit. The session, titled “2024 in Review: Milestones in Precision Health and the Road Ahead,” set the stage for the event by highlighting the pivotal advancements in precision medicine and health over the past year.

Speaking about the transformative developments in diabetes care, Dr. Mathieu remarked:
“We are living in the most exciting times for diabetes care, with groundbreaking disease-modifying therapies now at our fingertips. In type 2 diabetes, we have a surge of medications that not only treat obesity but also protect the heart, kidneys, and beta cells. In type 1 diabetes, we are identifying individuals in the early stages of the disease—before severe hyperglycemia and insulin dependence becomes a reality. This allows us to educate, monitor, and use therapies to delay progression in clinical diabetes.”

The day concluded with the Final Dual Keynote Session, ‘One Child Every Child, Care for Rare and FaceBase: Precision Health Programs Integrating Deep Phenotyping and Genomics ’. Keynote speakers Dr. Francois Bernier, Director of the Clinical Genetics Unit and Scientific Director of Precision Health at Alberta Children’s Hospital Research Institute, and Dr. Benedikt Hallgrímsson, Deputy Director of the Alberta Children’s Hospital Research Institute, shared insights on integrating deep phenotyping and genomics in precision health programs for pediatric patients with rare genetic conditions.

PMFG 2024 is held under the patronage of the Human Genome Organization (HUGO) and the Global Alliance for Genomics and Health, with Qatar Precision Health Institute as a strategic partner, the Children’s Hospital of Philadelphia as a knowledge partner, Qatar National Bank as the Official Diamond Patronage and Sponsor, and Msheireb Museums as a community partner.

Day 2 of PMFG 2024 on 4 December will feature:

• Morning Session: Implementing Genomics – Bridging Science and Healthcare
  • Keynote speaker, Dr. Nancy B. Spinner, Chief of Genomic Diagnostics at Children’s Hospital of Philadelphia, will discuss “Successes and Challenges of Genomic Testing in the NICU.”  
• Afternoon Session: Global Health Innovations
  • Keynote speaker, Dr. Gordon Sanghera, CEO of Oxford Nanopore Technologies, will deliver a special lecture on “Innovating in Genomics: Journey of a Health Spin-off.”  
• Late Afternoon Session: Capacity Building for Precision Medicine
  • Talks by Dr. Markus Wenk (HBKU), Dr. Medhat Askar (Qatar University), and Dr. Khaled Machaca (Weill Cornell Medicine Qatar).  

Day 3 of PMFG 2024 on 5 December will feature:

• Morning Session: Expert Forum on Custom-Made Therapies and Clinical Trials
  • Keynote speaker, Dr. Hakon Hakonarson (Director, Center for Applied Genomics, CHOP) will discuss Genomically-Informed Clinical Trials.
  • Keynote speaker, Dr. Chantal Mathieu (President, EASD) will discuss Arresting Type 1 Diabetes: Insights and Innovations from Leading Experts and Clinical Trials.
• Afternoon Session: Dialogue in Gene Therapy
  • Keynote speaker, Dr. James Wilson (President/CEO Gemma Biotherapeutics) will discuss Genetic Medicines for Rare Diseases.
• Closing Session: Precision Medicine in Qatar: Shaping the Future of Health through Genomics, Innovative Care, and Philosophies of Medicine
  • Talks by Dr. Paul Franks, Professor of Genetic Epidemiology at Lund University, Sweden and Dr. Ed Liu, Former President and CEO of The Jackson Laboratory, and Director of NCI-designated Cancer Center, USA.

For details and the agenda, please visit: https://www.sidra.org/events/research/pmfg/2024/program/ ​

01 December 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar’s first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

The trial follows Sidra Medicine’s launch of its Clinical Trials Program, aimed at offering a new lease of hope to children with rare and complex diseases. It primarily focuses on clinical trials that will benefit children in the Arab region, particularly those with rare diseases that lack effective treatment.

Sidra Medicine was selected as one of 22 leading centers worldwide to participate in the sunRIZE Phase 3 clinical trial. Led by Rezolute, a biopharmaceutical company specializing in rare diseases, the trial underscores Sidra Medicine’s growing prominence in pediatric endocrinology and its commitment to advancing innovative, patient-centered care.

Congenital hyperinsulinism is a complex condition that causes life-threatening hypoglycemia in children due to excessive insulin production. Many patients are unresponsive to existing therapies and often require invasive pancreatic surgery, which can lead to lifelong complications such as diabetes and pancreatic insufficiency.

Prof. Khalid Hussain, Division Chief of Endocrinology at Sidra Medicine, said: “This clinical trial represents a pivotal step in advancing care for congenital hyperinsulinism. Phase 3 trials compare new treatments to existing options in a diverse and larger patient population, providing evidence for regulatory approval based on effectiveness and safety. Our collaboration with Rezolute and international experts aims to develop a safer, non-invasive treatment option that could transform the lives of affected children and significantly reduce the need for surgery.”

The clinical trial was conducted on a 3-month-old Qatari girl, who was admitted to Sidra Medicine upon being diagnosed with congenital hyperinsulinism. After previous therapies to treat her condition were not successful, the child’s parents enrolled her for the SunRIZE trial as a last possible option to find an effective treatment.

“We are extremely pleased with the results of the trial as the young patient has responded favourably to the new medication. After careful monitoring to ensure she was in good health and was not experiencing any post-medication side-effects or risks, she has been discharged. Her blood sugar levels are now in the normal range, and she is feeding normally. We will continue to monitor her progress in the clinic every three months. We would like to thank the girl’s parents for putting their trust in us to find the best possible care and cure for their child,” continued Prof. Hussain.

The Congenital Hyperinsulinism trial, approved by Qatar’s Ministry of Public Health, was conducted by Sidra Medicine’s Endocrinology and Clinical Trials Program in collaboration with several internal departments, including Nursing, Pharmacy, IT, and the Institutional Review Board. Sidra Medicine is currently recruiting for more patients for the Phase 3 SunRIZE trial1, which is open to children aged between three months until 18 years of age.

Dr. Antonella Cioce, Clinical Trials Office Manager at Sidra Medicine, said: “This clinical trial highlights the exceptional teamwork and dedication at Sidra Medicine in advancing therapies for rare pediatric conditions. Families play a vital role in this journey, as their participation helps drive progress in developing innovative treatments. The trial represents a significant step toward transforming the care and outcomes for children with congenital hyperinsulinism, offering the potential to redefine treatment standards and bring hope to patients locally and globally.”

In addition to endocrine disorders such as Congenital Hyperinsulinism (CHI), Diabetes Type 1 (TD1), Sidra Medicine is also focusing on disorders and medical conditions such as neuromuscular conditions like Spinal Muscular Atrophy (SMA); Metabolic disorders like Homocystinuria (HCU) and pediatric cancers like Low Grade Glioma (pLGG).

Earlier in 2024, Sidra Medicine announced a groundbreaking protocol for treating congenital hyperinsulinism in a young Kuwaiti patient, marking another milestone in its mission to pioneer innovative treatments for rare diseases. For more details about Sidra Medicine’s Clinical Trials Program, please visit: www.sidra.org/research/clinical-research.

26 November 2024, Doha, Qatar – Sidra Medicine, a Qatar Foundation entity and a leading healthcare provider in Qatar, will host an insightful career guidance session as part of its highly anticipated Precision Medicine and the Future of Genomics 2024 Summit (PMFG 2024).

Titled, “Evaluating Your Career Choices: Opportunities in Big Pharma vs. Startups and Academia vs. Research Institutes”, the session will guide participants in navigating diverse career paths within biomedical and genomic research. It will offer a comprehensive overview of the opportunities and challenges in pharmaceutical companies, biotech startups, academia, and research institutes.

The session at PMFG 2024, has been especially set up for graduates and early-career professionals from universities and institutions in Qatar which have related research programs – such as Qatar University, Weill Cornell Medicine-Qatar, and Hamad Bin Khalifa University (HBKU).

Featuring a panel with Dr. Abdulrahman Al-Subaiey and Dr. Essam Abdelalim from Sidra Medicine; Dr. Dan Ory (Arbor Bio, USA); Dr. Rayaz Malik (Weill Cornell Medicine – Qatar) and with Dr. Georges Nemer (HBKU) serving as session chair, it will address skill-building, overcoming sector challenges, and alternative career routes.

Dr. Essam Abdelalim, Principal Investigator at Sidra Medicine, said: “Sidra Medicine is committed to empowering young professionals by providing access to cutting-edge knowledge and resources. This session highlights the wealth of research opportunities available in the country and emphasizes our role in nurturing the talent and skills of the next generation of Qatari scientists. We are excited to inspire young graduates to explore their potential and contribute to the scientific and medical advancements in Qatar and beyond.”

The session’s objectives include understanding career paths in each sector, evaluating personal career goals, and building skills needed to attain influential roles.

Dr. Abdulrahman Al-Subaiey, Postdoctoral Fellow at Sidra Medicine, said: “In today’s evolving biomedical landscape, it is essential for young professionals to understand the unique opportunities and challenges across various sectors. This session aims to equip participants with the knowledge and critical thinking skills to make informed career choices – fostering innovation and impact in science and medicine. For Qatari graduates and early career professionals, this is also an unparalleled chance to leverage the robust research ecosystem here in Qatar, gain insights from global experts, and take a proactive step toward shaping their futures by attending PMFG 2024.”

Sidra Medicine will also launch the Genomics Education and Navigating Excellence for Students program (GENEStars) at PMFG 2024. This new initiative aims to inspire and empower the next generation of leaders in precision medicine, providing a platform for students to engage with cutting-edge genomics research and innovation. GENEStars will become an annual feature of the summit, with outstanding participants recognized during the opening ceremony on 3 December – building a strong network of future ambassadors for the field in Qatar.

PMFG 2024 will be held under the patronage of the Human Genome Organization (HUGO) and the Global Alliance for Genomics and Health, with Qatar Precision Health Institute as a strategic partner, The Children’s Hospital of Philadelphia as a knowledge partner, Qatar National Bank as the Official Diamond Patronage and Sponsor, and Msheireb Museums as a community partner.

The PMFG 2024 Career Guidance Session will take place on the 5th of December from 9:40 AM to 10:30 AM at the Qatar National Convention Center (QNCC). Register here to be part of PMFG 2024 and shape the future of biomedicine.

24 November 2024, Doha, Qatar – Sidra Medicine, a member of Qatar Foundation, been awarded the esteemed ‘Samir Abbas Best Research Award’ for its pioneering study in reproductive medicine.

The recognition, awarded to a Qatar lead team and co-authored by a Qatari clinical embryologist,      Dr. Abdulla Almohammadi, was announced during the 31st Annual Scientific Meeting of the Middle East Fertility Society (MEFS), which was held from 21 to 23 November 2024 in Doha.

Titled “The reproductive potential of vitrified-warmed euploid embryos declines following repeated uterine transfers”, the study, a collaborative effort with Hamad Medical Corporation, was published earlier this year in ‘Reproductive Biology and Endocriology’. The research sheds light on the complexities of recurrent implantation failure (RIF) in fertility treatments – a condition that imposes significant psychological and financial challenges on patients undergoing multiple in-vitro fertilization (IVF) cycles.

Dr. Abdulla Almohammadi, Clinical Embryologist at Sidra Medicine and the study’s co-author, said: “Our findings highlight the intricate nature of RIF, which can be a frustrating and challenging burden on couples – both emotionally and financially. While preimplantation genetic testing for aneuploidy (PGT-A) addresses many cases, some remain unresolved. The research will also enable clinicians to tailor treatment strategies, including addressing underlying embryonic and uterine factors, that can improve outcomes and patient well-being. Receiving the Samir Abbas Best Research Award at MEFS 2024, further validates the far-reaching aspects of our study in being able to transform lives.”

The findings of the study will also provide valuable insights to enhance patient counseling and management strategies for individuals facing RIF, including the potential to improve overall success rates and patient experiences in fertility treatments.

Prof. Johnny Awwad, Executive Chair of Women’s Services at Sidra Medicine, said: “This recognition at MEFS 2024 is a tribute to the exceptional dedication of our team.  RIF being a stirring topic within the scientific community, the findings and perspective from Qatar contribute meaningful data to support clinical management and advance the understanding of this complex issue across the globe. It also underscores Qatar’s role as a leader in medical innovation and clinical research.”

The multidisciplinary RIFS research team also featured Dr. Fadi Choucair, Lead Clinical Embryologist and Dr. Lina El Taha, Clinical Fellow at Sidra Medicine; as well as Dr. Hasan Burjaq and Dr. Moza Albader from Hamad Medical Corporation. International contributions were led by Dr. Aurora Bueno Cavanillas, Director of Preventive Medicine and Public Health at the University of Granada, Spain.

MEFS 2024 brought together over 1,200 professionals from the fertility care community across the region. The conference served as a premier platform for showcasing advancements in fertility care, which fosters collaboration among physicians, embryologists, nurses, and researchers.

19 November 2024, Doha, Qatar – Sidra Medicine, the leading healthcare provider in Qatar under Qatar Foundation, will host the first-ever Gulf Pediatric Critical Care Conference “Forging Connections: Enhancing Care for Critically Ill Children” from 23-26 January, 2025.

The landmark conference is the first of its kind to be held in the Gulf Cooperation Council (GCC) and will feature local and international speakers and experts to discuss the latest advancements and best practices in pediatric critical care and intensive care (PICU). Key topics will include innovative strategies, clinical developments, and interdisciplinary collaboration that can enhance care for critically ill children.

The conference will host an exceptional lineup of global leaders in pediatric critical care. Dr. Ricardo Munoz, Chief of Cardiac Critical Care Medicine at Children’s National Hospital, will present on “Brain in the Cardiac Intensive Care” and “Critical Care Monitoring in the AI Era,” sharing his expertise in cardiac intensive care and telemedicine. At the resuscitation mini-symposium, Dr. Vinay Nadkarni of the Children’s Hospital of Philadelphia will deliver the plenary lecture, “Advances in Pediatric Resuscitation,” followed by Dr. Barney Scholefield from SickKids Hospital in Toronto, who will cover post-resuscitation neuro-critical care.

Dr. Ikram Haque, Conference Chair and Division Chief of Pediatric Critical Care at Sidra Medicine, said: “The Gulf Pediatric Critical Care Conference is an exciting opportunity for healthcare professionals to come together, share knowledge, and collaborate on addressing the complex medical, social, and ethical challenges that affect our young patient population in the GCC.  We are proud to host this one-of-a-kind event at Sidra Medicine as we work together to build the future of pediatric critical care in the region.”

Showcasing the breadth of GCC related collaboration, the conference’s organizing committee includes members from renowned institutions in Qatar, Kingdom of Saudi Arabia, the United Arab Emirates, Kuwait, Bahrain, Oman. International experts include members from Canada, Spain, Indonesia, Brazil, Argentina, the United Kingdom and the United States of America.

Dr. Patricia Abboud, Senior Attending physician and Medical Director in the PICU at Sidra Medicine said: “We are delighted to host the very first Gulf Pediatric Critical Care Conference at Sidra Medicine, where we will connect healthcare professionals from across the region and the globe to advance care for critically ill children. We encourage our peers and colleagues from the GCC and abroad, to join us as we shape the future of pediatric critical care through collaboration, innovation, and shared expertise.”

GCC nationals and residents interested in this exciting, inaugural event can register at Gulf Pediatric Critical Care – Online Single Registration and join a host of distinguished experts.